Jacobi Capital Management’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $410K | Sell |
11,157
-867
| -7% | -$41.1K | 0.02% | 466 |
|
|
2025
Q4 | $612K | Sell |
12,024
-7,554
| -39% | -$386K | 0.04% | 360 |
|
|
2025
Q3 | $1.09M | Buy |
19,578
+3,091
| +19% | +$181K | 0.07% | 265 |
|
|
2025
Q2 | $1.14M | Buy |
16,487
+3,163
| +24% | +$215K | 0.08% | 252 |
|
|
2025
Q1 | $925K | Buy |
13,324
+5,084
| +62% | +$420K | 0.07% | 259 |
|
|
2024
Q4 | $709K | Sell |
8,240
-73
| -0.9% | -$7.89K | 0.05% | 296 |
|
|
2024
Q3 | $990K | Buy |
8,313
+221
| +3% | +$29.5K | 0.07% | 251 |
|
|
2024
Q2 | $1.16M | Buy |
8,092
+157
| +2% | +$20.8K | 0.1% | 196 |
|
|
2024
Q1 | $1.02M | Buy |
7,935
+290
| +4% | +$34.5K | 0.09% | 200 |
|
|
2023
Q4 | $791K | Buy |
7,645
+2,911
| +61% | +$288K | 0.08% | 222 |
|
|
2023
Q3 | $430K | Buy |
4,734
+1,644
| +53% | +$145K | 0.05% | 298 |
|
|
2023
Q2 | $250K | Buy |
3,090
+94
| +3% | +$7.68K | 0.03% | 388 |
|
|
2023
Q1 | $238K | Sell |
2,996
-544
| -15% | -$38.6K | 0.03% | 383 |
|
|
2022
Q4 | $240K | Buy |
+3,540
| New | +$208K | 0.03% | 379 |
|
|
2021
Q4 | – | Sell |
-2,358
| Closed | -$113K | – | 1013 |
|
|
2021
Q3 | $113K | Buy |
2,358
+8
| +0.3% | +$387 | 0.01% | 499 |
|
|
2021
Q2 | $98K | Buy |
2,350
+14
| +0.6% | +$543 | 0.01% | 495 |
|
|
2021
Q1 | $79K | Buy |
2,336
+164
| +8% | +$5.84K | 0.01% | 492 |
|
|
2020
Q4 | $76K | Buy |
2,172
+68
| +3% | +$2.35K | 0.01% | 459 |
|
|
2020
Q3 | $73K | Buy |
2,104
+8
| +0.4% | +$267 | 0.01% | 429 |
|
|
2020
Q2 | $69K | Buy |
2,096
+14
| +0.7% | +$447 | 0.01% | 418 |
|
|
2020
Q1 | $63K | Buy |
2,082
+44
| +2% | +$1.31K | 0.01% | 391 |
|
|
2019
Q4 | $59K | Hold |
2,038
| – | – | 0.01% | 440 |
|
|
2019
Q3 | $53K | Buy |
2,038
+10
| +0.5% | +$253 | 0.01% | 447 |
|
|
2019
Q2 | $52K | Buy |
2,028
+16
| +0.8% | +$395 | 0.01% | 446 |
|
|
2019
Q1 | $53K | Buy |
2,012
+492
| +32% | +$12.1K | 0.01% | 403 |
|
|
2018
Q4 | $35K | Sell |
1,520
-3,634
| -71% | -$80.8K | 0.01% | 436 |
|
|
2018
Q3 | $121K | Buy |
5,154
+3,644
| +241% | +$88.9K | 0.03% | 292 |
|
|
2018
Q2 | $35K | Buy |
1,510
+18
| +1% | +$428 | 0.01% | 476 |
|
|
2018
Q1 | $36K | Buy |
1,492
+80
| +6% | +$2.1K | 0.01% | 445 |
|
|
2017
Q4 | $39K | Hold |
1,412
| – | – | 0.01% | 419 |
|
|
2017
Q3 | $35K | Buy |
1,412
+950
| +206% | +$21.5K | 0.01% | 416 |
|
|
2017
Q2 | $10K | Buy |
+462
| New | +$9.32K | ﹤0.01% | 572 |
|
Other funds holding NVO
DAM
F
Jacobi Capital Management's NVO Position: Q1 2026 in Review
Jacobi Capital Management reduced its Novo Nordisk (NVO) stake by 7.2% in Q1 2026, selling an estimated $41.1K and leaving 11,157 shares worth $410K. The position accounts for 0.02% of the portfolio, ranked #466.
Jacobi Capital Management first reported a position in NVO in Q2 2017 and has held it in 32 quarters since. The position peaked at $1.16M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.
- Jacobi Capital Management held 11,157 shares of Novo Nordisk worth $410K as of Q1 2026.
- Jacobi Capital Management sold 867 Novo Nordisk shares in Q1 2026, an estimated $41.1K.
- Novo Nordisk made up 0.02% of Jacobi Capital Management's portfolio in Q1 2026, its #466 holding.
- Jacobi Capital Management first reported a position in Novo Nordisk in Q2 2017 and has held it in 32 quarters since.
- Jacobi Capital Management's Novo Nordisk position peaked at $1.16M in Q2 2024.
- 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.
Based on Jacobi Capital Management's 13F filing for Q1 2026, filed 14 May 2026.